Everything drug pricing and policy, every day
And AbbVie joins the long list of companies that have struck deals with the White House
And early evidence of how the $2,000 out-of-pocket cap is helping patients ... and where it’s falling short
And list prices are falling on medicines that generated a total of $50 billion in sales last year
And a Health Affairs paper explains how 340B hospitals in 27 states can siphon savings that would otherwise accrue to state Medicaid programs
And how one pharmaceutical company expects to see revenue spike ... by slashing the list price of its medicine
The Jan. 1 pricing decisions for the 10 best-selling medicines might surprise you
And a critical 2026 trend -- dropping list prices on blockbuster drugs -- has begun with a 40%+ cut to Imbruvica’s price
And the results of the “Nobody Knows” Prediction Contest
